Effects of Ramelteon on Driving Ability
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary purpose of this study is to investigate the effects of bedtime administration of a single dose of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on next-morning on-road driving performance. In addition, the drugs' effects on balance are evaluated during the night, and the next morning residual effects on memory and psychomotor performance.
| Condition | Intervention | Phase |
|---|---|---|
|
Insomnia |
Drug: Ramelteon 8 mg Drug: Zopiclone 7.5 mg |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Crossover Assignment Masking: Double-Blind Primary Purpose: Prevention |
| Official Title: | A Study to Investigate the Residual Effects of Ramelteon (8 mg), Zopiclone (7.5 mg) and Placebo on Actual Driving, Memory, Psychomotor Performance and Mood |
- Standard Deviation of Lateral Position (SDLP); i.e. the weaving of the car.
- Standard Deviation of Speed (SDS)
- Mean Speed (MS)
- Mean Lateral Position (MLP)
- Word Learning test:Immediate recall, Delayed Recall, Recognition time & score
- Sternberg memory scanning test: reaction time and % errors
- Tracking task: RMS (tracking error)
- Divided attention test: RMS,reaction time and % errors
- DSST: number of copied symbols
| Estimated Enrollment: | 30 |
| Study Start Date: | March 2006 |
| Study Completion Date: | July 2006 |
Eligibility| Ages Eligible for Study: | 21 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- The subject is male or female, 21 - 55 years of age, inclusive
- The subject is capable of understanding and complying with the protocol requirements.
- The subject or the subject’s legally acceptable representative signs a written, informed consent form prior to the initiation of any study procedures.
- The subject, if female, is non-pregnant and non-lactating.
- Possession of a valid driver’s license for at least 3 years and a reported history of having driven at least 5000 km per year on average, for the last 3 years prior to entering into the trial.
- An SDLP level at the end of the driving test of the dress rehearsal that does not exceed 24 cm. This dress rehearsal is performed at Visit 1.
Exclusion Criteria:
- The subject has a known hypersensitivity to ramelteon, zopiclone or related compounds, including melatonin.
- The subject has participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to the first night of double-blind study medication, whichever is longer.
5.History or presence of any clinically significant gastrointestinal, cardiovascular, hepatic, renal, haematological, endocrine, respiratory, neurological or psychiatric disease 6.History of primary insomnia (DSM IV-TR criteria) within the past 6 months. 7.The subject has used any medication with psychotropic effects (e.g. antidepressants, anxiolytics, antihistamines) within 30 days of the initial visit.
Contacts and Locations| Netherlands | |
| Utrecht Institute for Pharmaceutical Sciences | |
| Utrecht, Netherlands, 3584CA | |
| Principal Investigator: | Joris Verster, PhD | Utrecht Institute for Pharmaceutical Sciences |
More Information
No publications provided by Utrecht Institute for Pharmaceutical Sciences
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00319215 History of Changes |
| Other Study ID Numbers: | 05/316, Studynumber:TAK-375/EC103, EudraCT Number 2005-005553-22 |
| Study First Received: | April 26, 2006 |
| Last Updated: | April 24, 2007 |
| Health Authority: | Netherlands: Medical Ethics Review Committee (METC) |
Keywords provided by Utrecht Institute for Pharmaceutical Sciences:
|
ramelteon zopiclone driving |
memory balance psychomotor |
Additional relevant MeSH terms:
|
Zopiclone Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs |
Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 21, 2013